Brief: uniQure Receives FDA Regenerative Medicine Advanced Therapy Designation For Investigational Gene Therapy AMT-130 In Huntington’s Disease
03/06/2024 13:31
June 3 (Reuters) - Uniqure NV UQ1.F :
* UNIQURE RECEIVES FDA REGENERATIVE MEDICINE ADVANCED
THERAPY
(RMAT) DESIGNATION FOR INVESTIGATIONAL GENE THERAPY AMT-130 IN
HUNTINGTON’S DISEASE
Source text for Eikon: ID:nGNEcgZcJx
Further company coverage: UQ1.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on uniQure
See all newsuniQure tumbles after updated Huntington's disease gene therapy data
UniQure plunges as Huntington's trial data disappoints investors (updated)
uniQure tumbles after updated Huntington's disease gene therapy data
UniQure's Huntington's therapy fails to significantly slow disease progression in trial
uniQure seeks US approval for Huntington's gene therapy after FDA reversal